GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzex Neuropharma Inc (OTCPK:TRRI) » Definitions » 14-Day RSI

Alzex Neuropharma (Alzex Neuropharma) 14-Day RSI : 80.43 (As of Jun. 02, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Alzex Neuropharma 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-02), Alzex Neuropharma's 14-Day RSI is 80.43.

The industry rank for Alzex Neuropharma's 14-Day RSI or its related term are showing as below:

TRRI's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 46.14 vs TRRI: 80.43

Competitive Comparison of Alzex Neuropharma's 14-Day RSI

For the Biotechnology subindustry, Alzex Neuropharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzex Neuropharma's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzex Neuropharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Alzex Neuropharma's 14-Day RSI falls into.



Alzex Neuropharma  (OTCPK:TRRI) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzex Neuropharma  (OTCPK:TRRI) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Alzex Neuropharma 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Alzex Neuropharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzex Neuropharma (Alzex Neuropharma) Business Description

Traded in Other Exchanges
N/A
Address
8275 South Eastern Avenue, Suite 200-168, Las Vegas, NV, USA, 89123
Alzex Neuropharma Inc is a development-stage biopharmaceutical company that has developed and patented precision therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquees) a French academic engineering and research institute.

Alzex Neuropharma (Alzex Neuropharma) Headlines

No Headlines